Press release
Desmoid Tumors Pipeline Outlook Report 2025: Insights on Key Pharma Players, Market Developments, and Transformative Therapies
Desmoid Tumors Pipeline
Discover the latest drugs and treatment options in the Desmoid Tumors Pipeline. Dive into DelveInsight's comprehensive report today! @ Desmoid Tumors Pipeline Outlook- https://www.delveinsight.com/sample-request/desmoid-tumors-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Desmoid Tumors Pipeline Report
• In May 2025, Nam Bui announced a study of this protocol is treatment. Systemic therapy with oral study agent, nirogacestat, will be given for 3 cycles (1 cycle = 28 days) followed by a single cryoablation procedure between Cycles 3 and 4, and then continued nirogacestat for Cycles 4 through 26. Treatment with nirogacestat may continue via this study for up to 24 months (26 cycles of treatment), unless there is progression of disease, intolerance, subject withdraws their consent, start of a new anticancer therapy, or until Subject Study Completion or Termination occurs.
• DelveInsight's Desmoid Tumors Pipeline report depicts a robust space with 4+ active players working to develop 4+ pipeline therapies for Desmoid Tumors treatment.
• The leading Desmoid Tumors Companies such as Immunome, Iterion Therapeutics and others.
• Promising Desmoid Tumors Pipeline Therapies such as AL102, Nirogacestat, Cryoablation, Sirolimus, Imatinib, FOG-001, mFOLFOX-6, REC-4881 and others.
Stay ahead with the most recent pipeline outlook for Desmoid Tumors. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Desmoid Tumors Treatment Drugs- https://www.delveinsight.com/sample-request/desmoid-tumors-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Desmoid Tumors Emerging Drugs Profile
• AL102: Immunome
AL102 is an investigational small molecule gamma secretase inhibitor currently being evaluated for the treatment of desmoid tumors - a debilitating soft tissue malignancy. AL102 is a potential once-daily oral treatment for desmoid tumors. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Desmoid Tumors.
The Desmoid Tumors Pipeline Report Provides Insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Desmoid Tumors with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Desmoid Tumors Treatment.
• Desmoid Tumors Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Desmoid Tumors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Desmoid Tumors market
Explore groundbreaking therapies and clinical trials in the Desmoid Tumors Marketed and Pipeline Drugs. Access DelveInsight's detailed report now! @ New Desmoid Tumors Drugs- https://www.delveinsight.com/sample-request/desmoid-tumors-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Desmoid Tumors Companies
Immunome, Iterion Therapeutics and others.
Desmoid Tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
Desmoid Tumors Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Unveil the future of Desmoid Tumors Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Desmoid Tumors Market Drivers and Barriers- https://www.delveinsight.com/sample-request/desmoid-tumors-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Desmoid Tumors Pipeline Report
• Coverage- Global
• Desmoid Tumors Companies- Immunome, Iterion Therapeutics and others.
• Promising Desmoid Tumors Pipeline Therapies- AL102, Nirogacestat, Cryoablation, Sirolimus, Imatinib, FOG-001, mFOLFOX-6, REC-4881 and others.
• Desmoid Tumors Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Desmoid Tumors Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Desmoid Tumors Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Desmoid Tumors Companies, Key Products and Unmet Needs- https://www.delveinsight.com/sample-request/desmoid-tumors-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Desmoid Tumors Pipeline Outlook Report 2025: Insights on Key Pharma Players, Market Developments, and Transformative Therapies here
News-ID: 4186973 • Views: …
More Releases from DelveInsight Business Research LLP
Sanfilippo Syndrome Pipeline Drugs Report 2025: Evaluating Novel Drug Candidates …
DelveInsight's, "Sanfilippo Syndrome Pipeline Insight 2025" report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Sanfilippo Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Sanfilippo Syndrome pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in…
Hunter Syndrome Pipeline Insights Report 2025: A Deep Dive into Emerging Therapi …
DelveInsight's, "Hunter Syndrome Pipeline Insight 2025" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Hunter Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hunter Syndrome pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in…
Mucopolysaccharidosis Type I Pipeline Outlook Report 2025: Comprehensive Insight …
DelveInsight's, "Mucopolysaccharidosis Type I Pipeline Insight 2025" report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Mucopolysaccharidosis Type I pipeline landscape. It covers the Mucopolysaccharidosis Type I pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Mucopolysaccharidosis Type I pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the…
Sandhoff Disease Pipeline Drugs Report 2025: Exploring Breakthrough Therapies, E …
DelveInsight's, "Sandhoff Disease Pipeline Insight 2025" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Sandhoff Disease pipeline landscape. It covers the Sandhoff Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Sandhoff Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Sandhoff Disease pipeline products in this space.
Discover the latest drugs…
More Releases for Desmoid
Desmoid Tumors Market Future Business Scope Analysis Report, Marketing Strategy, …
Introduction
The Desmoid Tumors Market focuses on a rare, locally aggressive, but non-metastatic type of soft tissue tumor that arises from fibroblasts. Also known as aggressive fibromatosis, desmoid tumors can occur anywhere in the body, but are most common in the abdomen, shoulder, and limbs. Although they do not spread to distant organs, they can cause significant morbidity due to local invasion and recurrence.
Over the past decade, treatment strategies have evolved…
Desmoid Tumors Market Poised for 6.8 % Growth, Set to Hit $4.13 Billion by 2029
How Are the key drivers contributing to the expansion of the desmoid tumors market?
The escalating prevalence of cancer is predicted to catalyze the expansion of the desmoid tumor market. Cancer is characterized by abnormal cellular growth in the body, which can uncontrollably spread and potentially damage nearby tissues and organs. With global cancer rates climbing, there has been a corresponding surge in demand for refined chemotherapeutic agents, having a favorable…
Top Factor Driving Desmoid Tumors Market Growth in 2025: Rising Global Cancer In …
How Big Is the Desmoid Tumors Market Expected to Be, and What Will Its Growth Rate Be?
The desmoid tumors market is set to grow from $2.97 billion in 2024 to $3.18 billion in 2025, at a CAGR of 7.3%. Growth is driven by advancements in medical imaging, genetic research, surgical innovations, and increased awareness and education on these tumors.
The desmoid tumors market is forecast to grow strongly, reaching $4.13 billion…
Top Factor Driving Desmoid Tumors Market Growth in 2025: Rising Global Cancer In …
How Big Is the Desmoid Tumors Market Expected to Be, and What Will Its Growth Rate Be?
The desmoid tumors market is set to grow from $2.97 billion in 2024 to $3.18 billion in 2025, at a CAGR of 7.3%. Growth is driven by advancements in medical imaging, genetic research, surgical innovations, and increased awareness and education on these tumors.
The desmoid tumors market is forecast to grow strongly, reaching $4.13 billion…
Desmoid Tumors Market Strategies 2024-2033: Segments, Analysis, Trends, Opportun …
"The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Desmoid Tumors Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $3.84 billion In 2028 At…
Desmoid Tumors Pipeline Outlook, Clinical Trials, FDA Approvals, and Companies 2 …
(Albany, United States) As per DelveInsight's assessment, globally, the Desmoid Tumors Pipeline constitutes 12+ key companies continuously working towards developing 12+ Desmoid Tumors Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.
In the Desmoid Tumors Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, Desmoid Tumors NDA approvals (if…
